Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: clinical implication.
The multilineage hematopoietic effects of IL-3 appear to be most important for its clinical use comprising especially leucocyte and platelet responses. This was demonstrated to be dose dependent characterising doses of 250 to 500 micrograms/m2/day subcutaneously as hematopoietic effective and well tolerable. Since preclinical data suggest synergism between IL-3 and GM-CSF hematopoietic effects of their sequential administration were evaluated in 15 patients with preserved hematopoietic function. An enhanced stimulation of megakaryopoiesis combined with more pronounced stimulation of granulopoiesis than IL-3 alone could be demonstrated. The cytokine combination of IL-3 and GM-CSF was thus used during chemotherapy induced myelosuppression. Data indicates beyond the known amelioration of myelosuppression by GM-CSF additional chances to enhance platelet recovery which can be of important clinical impact.
Frisch
J
J
Department of Clinical Research, Behringwerke AG, Marburg, Federal Republic of Germany.
Ganser
A
A
Hoelzer
D
D
Brugger
W
W
Kanz
L
L
Mertelsmann
R
R
Schulz
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000209:etiology / Q000628:therapy*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage*; D007958:Leukocyte Count; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D010976:Platelet Count
D007377:Interleukin-3; D016178:Granulocyte-Macrophage Colony-Stimulating Factor